ProCE Banner Activity

How I Manage CNS Metastases and Leptomeningeal Carcinomatosis in NSCLC

Clinical Thought
As targeted therapy prolongs survival in our patients with oncogene-driven NSCLC, CNS metastases and leptomeningeal carcinomatosis are more likely to develop as part of the disease course. Read my thoughts on what factors I consider when treating these challenging disease manifestations.

Released: April 28, 2020

Share

Faculty

Lyudmila Bazhenova

Lyudmila Bazhenova, MD

Associate Clinical Professor of Medicine
Division of Hematology-Oncology
University of California, San Diego
Medical Director, UC San Diego Moores Cancer Center Infusion Center
San Diego, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Lyudmila Bazhenova, MD

Associate Clinical Professor of Medicine
Division of Hematology-Oncology
University of California, San Diego
Medical Director, UC San Diego Moores Cancer Center Infusion Center
San Diego, California

Lyudmila Bazhenova, MD, has disclosed that she has received consulting fees from AstraZeneca, BeyondSpring, Blueprint, Boehringer Ingelheim, G1 Therapeutics, Genentech, Loxo Oncology, and Takeda and has ownership interest in Epic Sciences.